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Available online 6 December 2011Abstract Mesenchymal stromal cells (MSCs) are considered to be suitable vehicles for cellular
therapy in various conditions. The expression of reporter and/or effector protein(s) enabled both the identification of MSCs
within the organism and the exploitation in targeted tumor therapies. The aim of this study was to evaluate cellular changes
induced by retrovirus-mediated transgene expression in MSCs in vitro. Human Adipose Tissue-derived MSCs (AT-MSCs) were
transduced to express (i) the enhanced green fluorescent protein (EGFP) reporter transgene, (ii) the fusion yeast cytosine
deaminase::uracil phosphoribosyltransferase (CDy::UPRT) enzyme along with the expression of dominant positive selection
gene NeoR or (iii) the selection marker NeoR alone (MOCK). CDy::UPRT expression resulted in increased proliferation of
CDy::UPRT-MSCs versus naïve AT-MSCs, MOCK-MSCs or EGFP-MSCs. Furthermore, CDy::UPRT-MSCs were significantly more sen-
sitive to 5-fluorouracil (5FU), cisplatin, cyclophosphamide and cytosine arabinoside as determined by increased Caspase 3/7
activation and/or decreased relative proliferation. CDy::UPRT-MSCs in direct cocultures with breast cancer cells MDA-MB-
231 increased tumor cell killing induced by low concentrations of 5FU. Our data demonstrated the changes in proliferation
and chemoresistance in engineered MSCs expressing transgene with enzymatic function and suggested the possibilities for fur-
ther augmentation of targeted MSC-mediated antitumor therapy.
© 2011 Elsevier B.V. All rights reserved.Introduction
Human mesenchymal stromal cells (MSCs) represent an effi-
cient treatment to augment tissue regeneration, ameliorate
severe graft-versus-host disease post transplantation or modu-
late immune responses (Bernardo et al., 2009; Brooke et al.,
2007; Salem and Thiemermann, 2010; Caimi et al., 2010).⁎ Corresponding author at: Laboratory of Molecular Oncology, Cancer
Research Institute SAS, Vlarska 7, 833 91 Bratislava, Slovakia. Fax: +421
2 59327250.
E-mail address: exonkuce@savba.sk (L. Kucerova).
1873-5061/$ - see front matter © 2011 Elsevier B.V. All rights reserved.
doi:10.1016/j.scr.2011.11.006Clinical protocols were approved to use culture expanded
MSCs which fulfilled the minimal consensus criteria
((Dominici et al., 2006) and www.clinicaltrials.gov). Preclini-
cal treatment paradigms with genetically engineered MSCs as
anti-tumor agents have achieved both tumor-specific target-
ing and a potential to affect metastatic disease therapeutical-
ly (Kidd et al., 2009; Spaeth et al., 2008). Based on the
efficiency and biosafety studies conducted so far transgenic
MSCs might embody a therapeutic option for individual patient
treatment specifically if no other treatment was available.
The MSCs can be readily transduced via adenoviral, retrovi-
ral or lentiviral vectors (Shakhbazau et al., 2008; Gnecchi and
248 L. Kucerova et al.Melo, 2009). Marker transgene expression such as EGFP
(enhanced green fluorescent protein), RFP (red fluorescence
protein) or luciferase enabled to track the fate of MSCs within
the organism (Olivo et al., 2008; Wang and Chen, 2008; Hung
et al., 2010). Marker transgenes were also introduced in the
form of a fusion gene as it was recently reported for EGFP fu-
sion protein with IFNβ (Ling et al., 2010). Moreover, antitumor
effect was achieved by MSCs expressing enzymes combined
with respective prodrug and converted to cytotoxic metabo-
lite(s): thymidine kinase (HSV-TK)+ganciclovir or cytosine de-
aminase (CD)+5-fluorocytosine (5FC) (Kumar et al., 2008;
Klopp et al., 2011; Cavarretta et al., 2010; Kucerova et al.,
2007; Matuskova et al., 2010; Kucerova et al., 2008). Most of
the studies described therapeutic effect achieved in several
types of tumors including experimental metastasis models.
Engineered MSCs expressing transgenes with enzymatic func-
tion could be used for imaging properties as well. Hung et al.
(2005) detected radiolabelled substrate retention indicative
of HSV-TK-MSCs' participation in tumor stroma via micro-PET
imaging. Similarly, luciferase-expressing MSCs were used to
determine the sites and the extent of MSCs' engraftment in
the context of inflammation, injury and tumor disease (Kidd
et al., 2009).
The impact of retroviral transduction process on the MSCs
has to be carefully evaluated for any potential risk or
unwanted changes in cellular properties. Viral vector does
not seem to compromise the capability for multilineage differ-
entiation of MSCs or the expression of surface markers regard-
less of the expressed transgenic protein (e.g. EGFP (Lee et al.,
2001) or CDy::UPRT (Kucerova et al., 2007; Kucerova et al.,
2008)). Kallifatidis et al. (2008) described earlier senescence
of the transduced MSCs upon forced expression of EGFP or pu-
romycin acetyltransferase. Therefore they suggest the use of
engineered MSCs at low passages. Study of Piccoli et al.
(Piccoli et al., 2008) showed that retroviral transduction and
subsequent expression of dominant selection marker in stably
transduced MSCs induced an increased production of reactive
oxygen species although with no apparent biological conse-
quence in MSCs. The MSCs with some other types of transgenes
might potentially have increased risk of transformation in-
duced by insertional mutagenesis and/or exogenous transgene
interaction with the cellular signaling pathways (Momin et al.,
2010). However, engineered MSCs expressing the prodrug-
converting enzymes (such as HSV-TK or CD) have the “suicide”
concept included within, which might make these MSCs safer
for the therapeutic use. Nevertheless transgene with enzymat-
ic function metabolizes intracellular substrates thus being
capable to interfere with the cellular responses to various
stimuli. Although we and the others have previously reported
significant anti-tumor efficiency of transduced human mesen-
chymal stromal cells derived from human adipose tissue MSCs
(AT-MSCs) in several xenotransplant models (Kumar et al.,
2008; Fritz and Jorgensen, 2008; Vilalta et al., 2009), the ef-
fect of stable expression of exogenous protein on the MSCs'
properties has not been studied inmuch detail so far. Previous-
ly we have reported increased sensitivity of transduced CD-AT-
MSCs to 5-fluorouracil (5FU) and also noticed an increased pro-
liferation of transgenic CDy::UPRT-MSCs compared to the
untransduced counterparts. In the present study we have ana-
lyzed whether these changes were mediated via inherent ret-
rovirus sequences itself, transduction procedure or the
expression of transgene CDy::UPRT with enzymatic function.Results
Retroviral transductions and transgene expression
in AT-MSCs
In order to analyze properties of the transduced AT-MSCs we
have prepared three populations of transduced cells in paral-
lel. Transductions were performed in same cell passage num-
ber under identical culture conditions, plating density,
selection media and treatment time. Naïve AT-MSCs were
maintained under same culture conditions in the absence of
retrovirus and G418 treatment. MOCK-MSCs were transduced
with retroviral vector pJZ308 carrying G418 resistance gene
NeoR (aminoglycoside phosphotransferase II, (Wright and
Thompson, 1999)) only. The transduced MOCK-MSCs, EGFP-
MSCs and CDy::UPRT-MSCs could proliferate in 0.5 mg/
ml G418 containing media indicative of stable NeoR gene ex-
pression. Parental cells were completely eradicated after
8 to 10 days of incubation with G418. Transduction efficiency
and transgene expression were anticipated to be achieved in
99% of G418-resistant cells based on flow cytometry and fluo-
rescence microscopy evaluation in EGFP-MSCs (Figs. 1A–B).
5FC conversion to toxic derivatives of 5-fluorouracil led to sui-
cide effect at IC50=77 μM of 5FC in CDy::UPRT-MSCs, which
confirmed the enzymatic function of transgene (Fig. 1C).Proliferation analysis in engineered MSCs
Retroviral transduction and subsequent antibiotic selection
might have unintentionally enriched the transgenic MSCs
for rapidly proliferating subpopulations. We have previously
observed an increased proliferation of transduced CDy::
UPRT-MSCs in comparison to untransduced cells (unpub-
lished data). We decided to unravel whether this effect
could be attributable to the exogenous enzyme expression
in the respective cells. Population doubling time (PDT) in
CDy::UPRT-MSCs was significantly lower in comparison to
the corresponding naïve MSCs, MOCK-MSCs or EGFP-MSCs
shortly after transduction at low passages. Fluorescent
label retain assay followed by subsequent flow cytometry
analysis confirmed the higher proliferation rate of CDy::
UPRT-MSCs (Figs. 2A–B left panels). Although higher prolif-
eration was retained for many passages during subsequent
culture expansion of these cells, both assay methods demon-
strated loss of this proliferation advantage in high passage
CDy::UPRT-MSCs (Figs. 2A–B right panels). We could detect
earlier appearance of senescent cells within the extensively
expanded rapidly proliferating high passage CDy::UPRT-MSCs
(Fig. 2C). The MSCs were expanded further until their prolif-
eration arrest was observed and the appearance of morpho-
logical changes could be detected in the MSCs' cultures
(Fig. 2D). The evaluation of the β-Gal positive cell staining
revealed no substantial difference in numbers of senescent
cells per field in senescent cultures of naïve MSCs, MOCK-
MSCs, EGFP-MSCs and CDy::UPRT-MSCs.Chemosensitization in CDy::UPRT-MSCs
Intrinsic chemoresistance of the naïve MSCs has been described
previously (Kucerova et al., 2008; Li et al., 2004; Mueller et al.,
Figure 1 Retrovirus mediated transgene expression in MSCs. A. Parental AT-MSCs were retrovirally transduced to stably express
EGFP. The analysis by flow cytometry showed that 99.23% of transduced MSCs were EGFP-positive (right panel, Gate3+Gate4) in con-
trast to naïve MSCs (Gate3=3.25%, Gate 4=0.09%). Subpopulation of EGFPbright cells was observed in transduced EGFP-MSCs (Gate
3=9.23%, Gate 4=90.0%). B. Fluorescence microscopy confirmed the expression of EGFP (in green, nuclear DAPI counterstain —
blue, original magnification 100×). C. Relative proliferation of naïve and engineered MSCs in the presence of 5FC was determined
by MTS assay after 8 days. Suicide effect was induced in CDy::UPRT-MSCs with IC50(5FC)=77 μM. 5FC was non toxic for naïve MSCs,
MOCK-MSCs or EGFP-MSCs. *pb0.05.
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higher chemoresistance of MSCs to 5FU in comparison to the
human fibroblasts and other human tumor cells. However,
the expression of fusion CDy::UPRT gene significantly sensi-
tized transgenic MSCs to 5FU (Kucerova et al., 2007; Kucerova
et al., 2008). In order to exclude the possibility that increased
5FU sensitivity could be the consequence of a retroviral trans-
fer procedure itself, we have evaluated drug responsiveness
in transduced MSCs expressing various proteins. The induction
of apoptosis was performed by 48 h treatment with high doses
of chemotherapeutic drugs corresponding to the IC90 values
previously determined for the naïve MSCs. MOCK-MSCs and
EGFP-MSCs retained their resistance to apoptosis induction by
5FU at the level comparable to naïve MSCs (Fig. 3A). Contrast-
ingly, CDy::UPRT-MSCs exhibited induction of Caspase 3/7
activity upon 5FU treatment indicative of lower apoptotic
threshold. Combination treatment with leucovorin did not
further increase the apoptosis induction in any of the MSC sub-
populations (Fig. 3B). Both cisplatin and cyclophosphamide
treatment alone could increase the Casp3/7 activity in MSCs,
although to a rather limited extent. Combination treatment
with 5FU resulted in substantial several-fold higher apoptosis
induction in CDy::UPRT-MSCs only and not in the naïveMSCs, MOCK-MSC or EGFP-MSCs (Figs. 3C–D). These data have
demonstrated lower apoptotic threshold in MSCs expressing ex-
ogenous fusion enzyme CDy::UPRT.
Differential drug sensitivity was further confirmed in
a standard proliferation assay. Naïve MSCs, MOCK-MSCs
and EGFP-MSCs exhibited similar values for IC50 (5FU)=
20–40 μM. CDy::UPRT-MSCs were consistently significantly
more sensitive to 5FU and exhibited IC50 (5FU)=0.4 μM as de-
termined by luminescence viability assay after a 7 day treat-
ment (Fig. 4A). Although the sensitivity to 5FU gradually
decreased with an increasing MSCs' passage, CDy::UPRT-
MSCs always retained the hypersensitivity to the drug treat-
ments in comparison to transduced MOCK-MSCs, EGFP-MSCs
and naïve MSCs ((Kucerova et al., 2007; Kucerova et al.,
2008) and data not shown). Furthermore, leucovorin, cisplat-
in or cyclophosphamide treatments with doses resulting in
50% decrease in CDy::UPRT-MSCs' proliferation have shown
substantially lower decrease in proliferation in naïve MSCs,
MOCK-MSCs or EGFP-MSCs (Fig. 4B). Combination treatment
with 5FU could not achieve substantial increase in prolifera-
tion inhibition in MSCs although the inhibition in CDy::UPRT-
MSCs was significantly higher than in naïve MSCs, MOCK-MSCs
or EGFP-MSCs.
250 L. Kucerova et al.Transgene introduction did not change responses to 5-
azacytidine in any of the transduced cells in comparison to
naïve MSCs (Fig. 5A). Another pyrimidine analog cytosinearabinoside exhibited increased cytotoxicity towards MSCs
expressing CDy::UPRT, although this drug has not been de-
scribed to be metabolized by this enzyme (Fig. 5B). CDy::
Figure 3 Increased apoptosis is induced in CDy::UPRT-MSCs upon drug treatment. Naïve and transduced MSCs were treated with
indicated concentrations of 5FU alone (A) or in the combination with leucovorin (LEU) (B), cisplatin (cisPt) (C) or cyclophosphamide
(CPX) (D) for 48 h. Apoptosis induction was determined by Caspase-Glo3/7® Assay. Combination treatment of 5FU alone or 5FU with
cisplatin or cyclophosphamide induced increased Caspase 3/7 activity in CDy::UPRT-MSCs in comparison to naïve, MOCK-MSCs or
EGFP-MSCs. (RLU — relative luminescence units).
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doxorubicin metabolism, however, CDy::UPRT-MSCs exhib-
ited increased chemoresistance to low concentration of
doxorubicin treatment (Fig. 5C). These results have indicat-
ed the role of exogenously introduced enzyme CDy::UPRT in
the chemosensitization of CDy::UPRT-MSCs and excluded the
possible contribution of retroviral transduction process to
the MSCs' chemosensitization.Figure 2 CDy::UPRT-MSCs exhibit increased proliferation. A. Naïv
equal density to ensure the unrestricted exponential growth. Popul
MSC at early passage. *pb0.05. B. Cell proliferation after prolong
dye. Synchronized MSC cells were stained with DiI, one portion was M
culture media for 10 days. Fluorescence intensity was determined b
sage CDy::UPRT-MSCs by both methods. This effect was lost upon ext
high passage-MSCs from the previous analysis were tested for the cel
MSCs were found to be more prone to senescence as demonstrated b
sent from the high passage naïve, MOCK- or EGFP-MSCs (100× total m
started to exhibit proliferation arrest and morphological changes ind
as determined by the blue color could be detected in extensively pa
(a. 100×) and higher magnification (b.) as well in the expanded M
The expression of EGFP in respective extensively passaged was confIncreased cytotoxicity of 5FU in combination with
CDy::UPRT-MSCs in EGFP-MDA-MB-231 human
breast cancer cells
Finally, we have decided to test whether CDy::UPRT-MSC hy-
persensitivity to 5FU could be beneficial for increased by-
stander cytotoxicity towards target tumor cells in a direct
coculture. In our previous studies we have used CDy::UPRT-e and transduced MSCs at low and high passages were plated at
ation doubling time was significantly lower for the CDy::UPRT-
ed culture was performed by flow cytometry with Vybrant DiI
itC-arrested and both populations were maintained in standard
y flow cytometry. Higher proliferation was detected in low pas-
ensive culture expansion of transduced and naïve MSCs. C. Same
lular senescence by standard β-galactosidase assay. CDy::UPRT-
y the presence of β-galactosidase positive cells which were ab-
agnification). D. Senescence assay was repeated when the cells
icative of the cellular senescence. β-galactosidase positive cells
ssaged naïve MSCs (passage number 24) at lower magnification
OCK-MSC (c.), CDy::UPRT-MSC (d.) and EGFP-MSCs (e.), 400×.
irmed by fluorescence microscopy (f.).
Figure 4 MSCs chemosensitivity to 5-fluorouracil and combination treatment. Relative proliferation of naïve and transduced MSCs
was determined by luminescent viability assay after a 7 day incubation in the presence of indicated drugs. A. CDy::UPRT-MSCs were
significantly more sensitive to 5FU in comparison to naïve MSCs, MOCK-MSCs or EGFP-MSCs. B. CDy::UPRT-MSCs exhibited significant
decrease in relative proliferation in comparison to naïve MSCs, MOCK-MSCs or EGFP-MSCs in response to leucovorin (LEU), cisplatin
(cisPt) or cyclophosphamide (CPX) treatment alone or in combination with 5FU. *pb0.05.
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the prodrug 5-fluorocytosine in a standard enzyme/prodrug
therapeutic paradigm (Cavarretta et al., 2010; Kucerova
et al., 2007; Kucerova et al., 2008). However, breast cancer
cell line MDA-MB-231 was found to be relatively resistant
to CDy::UPRT-MSCs/5FC treatment. These tumor cells
exhibited IC50 (5FU)=30 μM as determined by MTS assay
(Fig. 6A). In order to distinguish between cell populations
in direct cocultures we have prepared fluorescently labeled
EGFP-MDA-MB-231 via retroviral transfer (Fig. 6B). Target
EGFP-MDA-MB-231 cells and effector CDy::UPRT-MSC cells
were mixed in a ratio 4:1 for assessment of bystander killing
effect in direct cocultures. Our results have shown that IC50
in EGFP-MDA-MB-231 cells could be achieved in direct cocul-
tures by 1.5 μM 5FU or 154 μM 5FC after a 3 day treatment
(Fig. 6C). Direct comparison has shown that 5FU sensitivity
of EGFP-MDA-MB-231 is 10-fold higher in the presence of
CDy::UPRT-MSCs in comparison to 5FU treatment of these
cells alone. CDy::UPRT-MSCs were capable of mediating in-
creased cytotoxic effect of 5FU on EGFP-MDA-MB-231.
In summary, we have compared cellular behavior of three
different types of retrovirally transduced MSCs (MOCK-MSCs,EGFP-MSCs and CDy::UPRT-MSCs) to naïve MSCs. We report an
increased proliferation of MSCs upon the expression of CDy::
UPRT transgene. Its expression could abrogate high intrinsic
chemoresistance of MSCs to 5FU and other chemotherapeutic
drugs, which could not be detected in MOCK- or EGFP-
transduced MSC. Our data suggest that the difference in re-
sponses to cytotoxic drugs was not attributable to retroviral
transfer procedure. We have shown that sensitization of
CDy::UPRT-MSCs to 5FU can be exploited to increase the
cytotoxicity of target EGFP-MDA-MB-231 human breast cancer
cells.Discussion
In our present study we compared the cellular properties of
engineered MSCs and naïve MSCs. Several lines of evidence
indicate for an absence of significant clonal dominance
drift that could potentially have occurred in genetically
engineered MSCs during the expansion in vitro. Mesenchymal
stromal cells derived from the adipose tissue actually comprise
rather heterogeneous mixture of the progenitor cells which
Figure 5 Chemosensitivity of MSCs to 5-azacytidine, doxoru-
bicin or cytosine arabinoside. MSCs were treated with indicated
drug concentrations for 7 days. Relative proliferation was deter-
mined by MTS assay. A. MSCs did not exhibit different sensitivity
to 5-azacytidine regardless of retroviral transduction or trans-
gene expression. B. Increased sensitivity to cytosine arabinoside
was demonstrated in CDy::UPRT-MSCs. C. CDy::UPRT-MSC cells
were more resistant to doxorubicin at low concentrations.
*pb0.05.
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et al., 2011). Prolonged culture expansion results in growth
pattern changes and may shift towards more homogeneous
population capable of the expansion under the particular cul-
ture conditions (Neuhuber et al., 2008). We have observed a
subpopulation of EGFPbright cells upon the transduction and se-
lection (Fig. 1B) which seem to be different from the majority
of the cells. This may account for the higher population dou-
bling time in the early passages. During the course of expan-
sion, culture conditions and extensive passages may change
the proportions of respective cells and thus also result in the
shortened PDT in the latter as observed in the high passagecells which still proliferated exponentially. The increased pro-
liferation rate in CDy::UPRT-MSC was retained during culture
expansion and lost only after numerous passages when some
of the cells started to approach the senescence and soon all
the MSCs became senescent. We did not observe a general in-
crease in MSC proliferation or chemosensitivity that could be
attributed to the retroviral transduction itself.
Engineered MSC cultures underwent replicative senes-
cence at similar passage number as respective naïve MSCs
from the same isolate with no appearance of aberrant clone
expansion. However, Kallifatidis et al. (2008) has reported
an earlier senescence in the lentivirus transduced and puro-
mycin selected MSC populations even though these cells did
not have compromised growth, differentiation capacity or
migration preferences. More importantly, Piccoli et al.
(Piccoli et al., 2008) have documented marked enhancement
of reactive oxygen species (ROS) production in retroviral
transduced MSCs linked to a specific change in activity of mi-
tochondrial respiratory chain complex I. Alteration in ROS
production reported in mock-transduced MSCs was found
not to be cytotoxic and independent of vector backbone
and/or integration modalities. Their data link increased
ROS production to the impact of the antibiotic resistance
gene product aminoglycoside phosphotransferase II and its
interaction with mammalian protein kinase activities. G418
(or Geneticin®) inhibits protein synthesis by known mecha-
nism (Wright and Thompson, 1999), but it has also other
pleiotropic effects (Dalhoff, 1987). However, G418 antibiotic
was withdrawn from culture medium and thus its effect is un-
likely to be involved in observed differences.
The MSCs were shown to exhibit high chemoresistance to
various cytotoxic drugs (Li et al., 2004; Mueller et al., 2006;
Liang et al., 2011). Clinically relevant concentrations of indi-
vidual chemotherapeutic agents (paclitaxel, vincristine, eto-
poside highdose cytarabine and high-dose dexamethasone)
led to more than 20% reduction of viable cell numbers after
a short term 3 day treatment. These published data sug-
gested that chemotherapeutic agents could induce apoptosis
of MSCs which accounted for the decrease in cell viability.
High apoptotic threshold for cisplatin was linked to the sup-
pression of Casp-9 activity (Mueller et al., 2006). We suggest
that the chemoresistance in MSCs could be attributed to the
overexpression of multidrug resistance-associated protein
MRP1 (ABCC1), which has been reported in 5FU resistant
cancer cells (Szakacs et al., 2006). ATP-binding cassette
members ABC A3 (ATP-binding cassette, subfamily A, mem-
ber 3), ABC G2 (Bcrp) and ABC B5 expression have been also
shown in AT-MSCs (Kucerova et al., 2008; Szakacs et al.,
2006; Frank et al., 2003). These transporters may contribute
to MSCs' resistance against multiple cytotoxic drugs.
Previously we have demonstrated that AT-MSCs express en-
zymes relevant for the intracellular metabolism of 5FU such as
thymidylate synthase (TS), thymidylate phosphorylase (TP),
orotate phosphoribosyltransferase (OPRT) and dihydropyrimi-
dine dehydrogenase (DPD) (Kucerova et al., 2008). DPD rapidly
degrades 5FU and contributes to 5FU catabolism to produce in-
active metabolite dihydrofluorouracil (Longley et al., 2003).
Following entry into the nucleotide salvage pathway, 5-FU is
further metabolized. CDy::UPRT recombinant fusion enzyme
possesses both capability to convert 5FC to 5FU and furtherme-
tabolizes 5FU to 5-fluorouridine-5′-monophospahte (FUMP).
We anticipate that the abundant production of FUMP by
Figure 6 CDy::UPRT-MSCs increased 5FU-mediated cytotoxicity in EGFP-MDA-MB-231. A. Breast cancer cells MDA-MB-231 and CDy::
UPRT-MSCs were treated with 5FU and relative proliferation was determined by MTS assay. IC50 was determined to be comparable for
these cells, 30 μM to 38 μM 5FU, respectively. B. Flow cytometric analysis has shown that 90.76% of EGFP-MDA-MB-231 cells were
EGFP-positive post transduction. 7-Aminoactinomycin D viability dye was used to verify that non-viable EGFP-MDA-MB-231 have
lost EGFP fluorescence (right panel, upper right quadrant). C. Target EGFP-MDA-MB-231 cells were cocultured with effector CDy::
UPRT-MSC cells in a ratio 1 to 4 in the presence of 5FC or 5FU for 3 days. Proliferation of EGFP-MDA-MB-231 cells was evaluated by
determining relative fluorescence. Coculture experiments have shown potent augmentation of killing effect by CDy::UPRT-MSCs
and a 10-fold increase in tumor cell sensitivity to 5FU in the presence of transduced cells.
254 L. Kucerova et al.exogenously delivered UPRT plays significant role in chemosen-
sitization of CDy::UPRT-MSCs to 5FU by avoiding DPD mediated
5FU degradation. Exogenous UPRT combinedwith tissue specif-
ic expression significantly increased efficiency of 5FU-based
chemotherapy in prostate tumor cells via suicide effect (Zhao
et al., 2009). In our study we have demonstrated pronounced
bystander cytotoxicity of CDy::UPRT/5FU treatment modality
in breast cancer cells. This combined treatment of EGFP-
MDA-MB-231 cells was much more efficient when compared to
5FU treatment alone or CDy::UPRT/5FC that has shown limited
efficiency in vivo ((Kucerova et al., 2011; Kucerova et al.,
2010) and unpublished data). As serum and intratumoral levels
achievable by 5FC and 5FU administration are limited, we sug-
gest that therapeutic combination of CDy::UPRT-MSCswith low
dose of 5FU would be more effective in comparison to CDy::
UPRT-MSCs with maximum tolerated dose of 5FC in vivo.
Cyclophosphamide, cisplatin and some other treatments
have been described to induce TP expression, which is benefi-
cial for the anticancer effect (Toi et al., 2005; Walko and
Lindley, 2005). In our work, we have demonstrated that
combined 5FU treatment with either cyclophosphamide orcisplatin led to strong apoptosis induction as demonstrated
by activation of Caspase 3/7 in CDy::UPRT-MSCs. Leucovorin
combination treatment with 5FU has an apparently different
mechanism of action although with similar outcome on de-
creased cell proliferation in CDy::UPRT-MSCs ((Thirion et al.,
2004) and our data). Another study has reported cisplatin-
mediated depression in enzyme activity of DPD leading to cy-
totoxic synergistic action of 5FU (Miyazaki et al., 2006). Re-
sponses to nucleotide analogs 5-azacytidine have not been
affected in engineered MSCs, however cytosine arabinoside
inhibited proliferation of CDy::UPRT-MSCs to a higher extent.
We have found increased resistance of these MSCs to low con-
centrations of anthracycline antibiotic doxorubicin. We hy-
pothesize that the enzymatic action of CDy::UPRT transgene
could have contributed to cellular resistance to cytotoxic
drug by interferring with the nucleotide salvage pathways
and provided the transduced cells with a survival advantage.
Moreover, these data add further indications to the preclinical
testing of our therapeutic paradigm in order to increase its ef-
ficiency. Based on the presented data we suggest to augment
the CDy::UPRT-MSC-mediated tumor targeted therapy with
255Increased proliferation and chemosensitivity of MSCs expressing yeast fusion cytosine deaminase(low doses of) 5FU and/or in combination with doxorubicin. In
order to achieve maximum tumor growth suppression the
drugs which induce rapid apoptosis induction in therapeutic
CDy::UPRT-MSCs should be avoided.
In summary, our data add further knowledge to the use of
engineered MSCs for the experimental applications. We have
shown that unless specific transgene had been introduced
into these cells to interfere directly with the metabolic path-
way(s) of cytotoxic drug, no significant difference in behavior
could have been determined between the naïve and trans-
duced MSCs. Fluorescent and dominant selection marker
expressing MSCs are useful tools to further examine the role
of MSCs and the function in a stromal tumor compartment.
These transgenes could be also used for the downstream anal-
ysis of homing, persistence, differentiation and other attri-
butes of the MSCs' progeny. Nevertheless, these studies
should be also corroborated with those employing endogenous
markers within the MSCs (Klopp et al., 2011) as it was shown,
that EGFP expression declined rapidly to undetectable level
post-transplantation in vivo and was reversed only upon re-
establishment of EGFP transduced cells in cell cultures
(Ronsyn et al., 2007). However, the future clinical application
of genetically modified MSCs still requires further investiga-
tion and their translation into cancer treatment remains the
matter of intense debate (Momin et al., 2010).
Conclusion
The data presented in our study have shown that intracellular
expression of fusion yeast cytosine deaminase::uracil phosphor-
ibosyltransferase increases the proliferation of transducedmes-
enchymal stromal cells. CDy::UPRT-MSCs exhibited both lower
apoptotic threshold and decreased chemoresistance, which
was not observed in the retrovirally transduced counterparts
with selection or fluorescent marker protein. CDy::UPRT-MSCs
were highly sensitized to 5FU perhaps by its efficient conversion
to downstream toxic metabolites that further interfered with
DNA and/or RNA synthesis thus avoiding the degradation to in-
active metabolite(s). Direct cocultures with breast cancer
cells MDA-MB-231 have shown a potent tumor cytotoxic effect
in novel treatment paradigm of CDy::UPRT/5FU in vitro.
Materials and methods
Chemicals
Following chemicals were used for cell treatments: 5-
fluorocytosine, 5-azacytidine and 5-fluorouracil obtained
from Sigma (St. Louis, MO), leucovorin (Lachema, brno,
Czech Republic), doxorubicin and cisplatin (EBEWE Pharma
Austria), cyclophosphamide (Endoxan, BAXTER Oncology
GmBH, Germany), cytosine arabinoside (Cytosar, PFIZER
Europe, Kent, Great Britain). Other chemicals were pur-
chased from Sigma (St. Louis, MO) if not stated otherwise.
Cells
Human breast adenocarcinoma cell line MDA-MB-231 (ATCC®
Number : HTB-26™) was cultured in high-glucose (4500 mg/
ml) Dulbecco's modified Eagle medium (DMEM, PAALaboratories GmbH) supplemented with 10% fetal bovine
serum (FBS, Biochrom AG), 10.000 IU/ml penicillin (Biotika,
Part. Lupca, Slovakia), 2 mM glutamine, 5 μg/ml streptomy-
cin and 2.5 μg/ml amphotericin (Sigma, St. Louis, MO).
AT-MSCs were derived by plastic adherence technique as
previously described (Kucerova et al., 2007). Cells were ex-
panded in low-glucose DMEM (1000 mg/ml) with GlutamMAX™
(PAA Laboratories GmbH) supplemented with 10% HyClone®
AdvanceSTEM™ Mesenchymal Stem Cell Growth Supplement
(Thermo Scientific) and antibiotic mix as above. AT-MSCs were
routinely screened for surface marker expression as CD44+,
CD73+, CD90+, CD105+, CD14−, CD34−, CD45− population.
AT-MSCs were characterized by trilineage differentiation as
determined by the capability to differentiate into adipogenic,
osteogenic and chondrogenic lineages (data not shown). Con-
clusions were drawn from similar results of experiments per-
formed with three different isolates.
Following retrovirus constructs were used for transfec-
tions: pJZ308 mock plasmid with NeoR dominant selection
marker (kindly provided by J. Hlavaty, Institute of Virology,
Department of Pathobiology, University of Veterinary Medi-
cine, Vienna, Austria), pST2 (Kucerova et al., 2007) and
pAPGFP (Matuskova et al., 2010). All plasmids were carrying
same retrovirus backbone from plasmid pJZ308 (Hlavaty
et al., 1997). Retrovirus vectors were bicistronic constructs
with EGFP or fusion yeast CDy::UPRT gene separated by in-
ternal ribosome entry site sequence from NeoR gene as
depicted in (Kucerova et al., 2008).
EGFP-MDA-MB-231 cell line stably expressing enhanced
green fluorescent protein (EGFP) was prepared according to
Matuskova et al. (2010) with some modifications. Sub-
confluent MDA-MB-231 cultures were transduced once with
virus-containing media supplemented with 5 μg/ml protamine
sulfate. Cells were cultivated in selection media containing
0.5 mg/ml G418 for 10 days. EGFP expression in transduced
EGFP-MDA-MB-231 cells was verified by flow cytometry on
cells counterstained with 7-aminoactinomycin D (Sigma, St.
Louis, MO) for viability on EPICS ALTRA® (Beckmann Coulter)
flow cytometer equipped with Expo 32 program.
In order to prepare transgenic AT-MSCs, cells at passage 1
to 2 were transduced thrice in three consecutive days with
virus-containing media supplemented with 5 μg/ml protamine
sulfate. Cells were cultivated in selection media containing
0.5 mg/ml G418 for 10 days. Parental untransduced AT-MSCs
served as a control for selection that was terminated when
all parental cells were dead. EGFP expression was confirmed
by flow cytometry as described above and visualization with
nuclear counterstain (4′,6-diamidino-2-phenylindole, DAPI)
in EGFP-MSCs was done on PALM MicroBeam (Carl Zeiss Micro-
Imaging GmbH, Jena, Germany) equipped with fluorescence
detection in FITC and DAPI channels and figures were merged.
Transduced MSC did not show any significant change in MSCs'
characteristics such as surface marker expression or trilineage
differentiation capability (data not shown).
Population doubling time (PDT) was calculated for the
MSC at early passage and after prolonged culture according
to the formula G=t log 2/log Nt− log No, where t=time pe-
riod, Nt=number of cells at time t, No=initial number of
cells. Cells were used for the experiments within 8 passages
after the G418 selection and designated as low passage cells
(cells underwent less then 10 PDT). For the proliferation and
senescence assay, MSCs were cultured for prolonged time
256 L. Kucerova et al.and evaluated after more than 15 passages post transduction
(high passage cells, cells underwent more then 25 PDT).
All cells were kept in humidified atmosphere and 5% CO2
at 37 °C.
Proliferation evaluation by flow cytometry
In order to compare proliferation rates of engineered and pa-
rental MSCs, cells were synchronized overnight in DMEM with-
out any MSCs' Growth Supplement. Synchronized MSCs were
then labeled with 5 μL of Vybrant DiI (Invitrogen, Carlsbad,
CA) diluted in 1 ml PBS per 1×106cells for 20 min at 37 °C.
One part of these cells was arrested by treatment with
10 μg/ml Mitomycin C (Mit-C, Kyowa, Hakko Ltd UK) diluted
in culture medium for 3 h and washed. Proliferating and
arrested cells were kept in standard culture medium for
10 days. Cells were then trypsinized, washed and fluorescence
intensity was determined by flow cytometry by comparing
shift in fluorescence intensity of proliferation-arrested MSCs
and proliferating cells. DiI fluorescent staining does not inter-
fere with EGFP fluorescence, therefore this method is suitable
for EGFP-MSCs stably expressing fluorescent reporter protein.
Proliferation assays
Quadruplicates of 2000–2500 engineered or parental MSCs per
well were seeded in 96-well plates overnight. For cytotoxic
treatments, medium was aspirated and MSCs' culture medium
with diluted drugs was added to cells for indicated time.
Relative cell proliferation was evaluated by CellTiter-Glo™
Luminescent Cell Viability Assay (Promega Corporation, Madi-
son, WI) in quadruplicates in white-walled 96-well on LUMIstar
GALAXY reader (BMG Labtechnologies, Offenburg, Germany).
Values were expressed as relative luminescence (RLU),
where relative luminescence of untreated cells was taken as
reference. Alternatively, relative proliferation of MSCs
was determined by CellTiter® 96 AQueous One Solution Cell
Proliferation Assay (MTS Assay, Promega). Ten μl of 5 mg/ml
3-(4-5-dimethyl-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sul-
fophenyl)-2H-tetrazolium salt (MTS) diluted in 90 μl DMEM
was added to each well and incubated for 2 h at 37 °C. Absor-
bance values were read out spectrophotometrically at
492 nm by PolarStar OPTIMA reader (BMG Labtechnologies,
Offenburg, Germany). Results were expressed as relative
proliferation, where the proliferation of cells in standard
culture medium DMEM without any treatment was set to
100% by default. Experiments were performed at least
twice with similar results and representative experiment re-
sult is shown, values are expressed as means±SD.
Apoptosis assays
Quadruplicates of 5000 engineered or naïve MSCs per well
were seeded in 96-well white walled plates overnight.
Drugs were added to the cells for indicated period of time
and the Caspase-3/7 activity was determined by the
Caspase-Glo® 3/7 Assay (Promega Corporation, Madison,
WI) on LUMIstar GALAXY reader (BMG Labtechnologies,
Offenburg, Germany). Values were determined in relative
luminescence units (RLU).Senescence assay
Senescence β-galactosidase Staining Kit (Cell Signaling,
Danvers, MA) was used to check the senescence in MSCs.
One×105 cells were seeded on 6-well plates and after 24 h
were fixed and stained according to the manufacturer's pro-
tocol. Processed wells were sealed with parafilm, covered
with alufoil and incubated overnight at 37 °C without CO2.
Next day the cells were inspected for development of blue
color under a light microscope (100× total magnification).
Relative fluorescence detection in direct cocultures
EGFP-MDA-MB-231 cells were mixed with CDy::UPRT-MSCs
(ratio 4:1) to achieve final numbers of 4000 EGFP-MDA-MB-
231 with 1000 CDy::UPRT-MSCs per 200 μl culture media
per well and plated in black-walled 96-well plates (Greiner
Bio-One Intl. AG). In an independent plate, 4000 EGFP-
MDA-MB-231 per 200 μl culture media were plated per well
for overnight. On the next day, medium was aspirated and
MSC culture medium with diluted drugs (5FC or 5FU) was
added to cells for indicated period of time. Culture medium
was carefully aspirated, wells were washed with PBS and
100 μl 0.2% Nonidet P-40 in PBS was added to each well. Rel-
ative proliferation of EGFP expressing cells was evaluated by
determining relative green fluorescence on PolarStar OPTI-
MA reader (BMG Labtechnologies, Offenburg, Germany).
Values were expressed as means of relative fluorescence
measured in quadruplicates±SD, where EGFP-MDA-MB-231
florescence in culture medium DMEM with or without CDy::
UPRT-MSCs was set to 100% by default. It was previously de-
termined, that there was a linear correlation between fluo-
rescence intensity and number of EGFP expressing cells
under these experimental culture conditions and cell densi-
ties. CDy::UPRT-MSCs' presence in direct coculture with
EGFP-MDA-MB-231 did not affect cell fluorescence (data
not shown).
Statistical analysis
Studies involving comparison between two groups were ana-
lyzed by unpaired Student's t-test. One-way ANOVA was
employed in experiments with more than two groups. A
value of pb0.05 was considered statistically significant.Acknowledgments
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